CytoDyn CYDY
OTC CYDY
$0.20 +0.00 (+0.00%)
At close: Sep 30, 2026 · 4:00 PM EDT

CytoDyn (CYDY) Change in Receivables (2021)

Updated

CytoDyn (CYDY) posted Change in Receivables of $184,000 for fiscal Q2 2022 (quarter ended Nov 30, 2021), up 348.8% from the prior quarter.

Analysis

CytoDyn (CYDY) Change in Receivables (2021) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change Receivables (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn 1.35 Bn
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn 1.37 Bn
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn -
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn -
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn -
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn 1.09 Bn
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn 333.00 Mn
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn -
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn 140.20 Mn
10 CytoDyn 274.70 Mn 274.70 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Nov 30, 2021 184,000.00
Aug 31, 2021 41,000.00
API Access

CytoDyn Change in Receivables API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=change-in-receivables&ticker=CYDY&period=max&api_key=YOUR_API_KEY